Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 13
GLP-1s and unapproved peptides: review
Why a clinician or pharmacist needs the full product list before assessing prescription drugs, GLP-1 medicines and unapproved peptides.
Retatrutide vs semaglutide: the trial
Lilly's reported TRANSCEND-T2D-2 results put retatrutide ahead of semaglutide on average HbA1c and weight change, with important limits.
TMSB4X and Glioma Spread: Study
A preclinical study linked oligodendrocyte-derived thymosin beta-4 to glioma invasion, without testing a human therapy or a TB-500 product.
BPC-157 Liver Review: Evidence Limits
A 2026 narrative review summarized broad rodent findings for BPC-157 but provided no controlled evidence of efficacy in human liver disease.
CagriSema in Type 2 Diabetes: Meta-Analysis
A 2026 Bayesian meta-analysis found clear benefits versus placebo, but the added HbA1c effect versus dose-matched semaglutide was uncertain.
GLP-1 After Heart Transplant: Study
A 14-center retrospective study found improved metabolic markers in selected heart transplant recipients, without proving comparative benefit or graft safety.
GLP-1 Oral Health Signals: FAERS
A 2026 FAERS analysis found oral-health reporting signals for five GLP-1 medicines, but it could not estimate patient risk or prove causation.
BPC-157 and TB-500 in Orthopaedics
A 2026 review found preclinical signals but no controlled human orthopaedic efficacy evidence for BPC-157, thymosin beta-4 or TB-500.
Semaglutide and Alcohol Withdrawal in Rats
A 2026 rat study reported less alcohol intake and anxiety-like behavior, but it does not establish treatment of alcohol use disorder in people.
Semaglutide Panic Attacks: FAERS Readout
A 2026 FAERS analysis found an adjusted reporting signal, but timing and evidence from other designs did not support a consistent causal link.
Semaglutide in Hemodialysis Study
A 2026 target-trial emulation associated semaglutide with lower mortality and hospitalization than pooled comparators, without proving causation.
Tirzepatide Use in Germany: Database Study
An early German utilization study described who started tirzepatide and recorded dose patterns, without testing effectiveness or a preferred dose.